The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development
In this paper I examine how the promissory value of genetics is constituted through processes of scale and scaling, focussing on the relationship between “rare” and “common” forms of disease. I highlight the bodies and spaces involved in the production of post-genomic knowledge and technologies of A...
| 主要作者: | |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Taylor & Francis Group
2020-01-01
|
| 叢編: | New Genetics and Society |
| 主題: | |
| 在線閱讀: | http://dx.doi.org/10.1080/14636778.2019.1637718 |
| 總結: | In this paper I examine how the promissory value of genetics is constituted through processes of scale and scaling, focussing on the relationship between “rare” and “common” forms of disease. I highlight the bodies and spaces involved in the production of post-genomic knowledge and technologies of Alzheimer's disease and the development of new disease-modifying drugs. I focus on the example of the development of a monoclonal antibody therapy for Alzheimer's disease. I argue that the process of therapeutic innovation, from genetic studies and animal models to phase III clinical trials, reflects the persistent importance of a genetic imaginary and a mutually constitutive relationship between the rare and the common in in shaping visions of Alzheimer's disease medicine. Approaching this relationship as a question of scale, I suggest the importance of attending to how and where genomic knowledge is “scaled” or proves resistant to scaling. |
|---|---|
| ISSN: | 1463-6778 1469-9915 |